SEC Tracker
Get the app

Silence Therapeutics SLN

Silence Therapeutics agrees to merger

Additional proxy materials

Form
DEFA14A
Filed
Importance
Routine
  1. Merck KGaA to acquire Silence Therapeutics
  2. Per share consideration of $6.67
  3. Per ADS consideration of $20.00
  4. Requires shareholder approval

Written from the DEFA14A on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Silence Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Cardiff Oncology CRDF public float $205M, Jun 30, 2025
  2. Tvardi Therapeutics TVRD public float $207M, Jun 30, 2025
  3. Rezolute RZLT public float $204M, Dec 31, 2025
  4. Natures Sunshine Products NATR public float $211M, Jun 30, 2025
  5. Rocket Pharmaceuticals RCKT public float $213M, Jun 30, 2025